LB Pharmaceuticals appoints Joseph Miller as chief financial officer
The executive brings over two decades of biopharmaceutical finance experience to guide the company through upcoming clinical trial results and potential product commercialization.
See the latest news and media coverage for LB Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing neuropsychiatric therapies
lbpharma.usLast updated
In short: LB Pharmaceuticals accelerated Phase 3 schizophrenia data timelines and secured $150 million to extend its cash runway into 2029.
The executive brings over two decades of biopharmaceutical finance experience to guide the company through upcoming clinical trial results and potential product commercialization.
The funding will support pipeline expansion of LB-102 into new indications and for working capital.
The company now expects to report topline data in first half of 2027, ahead of prior guidance.
Initiated pivotal Phase 3 NOVA-2 trial in schizophrenia and Phase 2 ILLUMINATE-1 trial in bipolar depression, with $365.6 million cash.
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatry.
NEW YORK (AP) — NEW YORK (AP) — LB Pharmaceuticals Inc. (LBRX) on Tuesday reported a loss of $51.6 million in its second quarter. The...
LB Pharmaceuticals (LBRX) reported Q2 2026 results and highlighted progress for LB-102, with Phase 3 NOVA-2 schizophrenia topline data now expected in 1H 2027. The...
On August 11, 2026, LB Pharmaceuticals announced a $150 million private placement to accelerate...
Track LB Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to LB Pharmaceuticals and other trending companies.